Donepezil to be funded for the treatment of Alzheimer’s disease
As the world’s population ages, the number of people affected by Alzheimer’s disease, the most common form
of dementia, will rise rapidly. There is currently no treatment available that can prevent the onset of Alzheimer’s
disease or its progression. Management is focused on symptomatic treatment using lifestyle, behavioural and pharmacological
methods, where appropriate. The aim of treatment is to improve quality of life for both the person with Alzheimer’s
disease and their family.
PHARMAC recently announced that donepezil, a medicine used in the management of Alzheimer’s disease, will be funded
on the Pharmaceutical Schedule from November 1, 2010. The Donepezil-Rex brand (donepezil hydrochloride) will be available
for prescription by any prescriber, and will not require Special Authority approval or specialist recommendation.
Donepezil is a specific and reversible inhibitor of acetylcholinesterase, registered in New Zealand for the symptomatic
treatment of Alzheimer’s disease and vascular dementia. Some guidelines recommend that donepezil (and other acetylcholinesterase
inhibitors) only be used in moderate Alzheimer’s disease (rated by a MMSE* score
of 10 – 20).1,2 However there is evidence that donepezil has a positive effect in some people with severe3,4 and
mild Alzheimer’s disease.5 In practice, donepezil may be used in any patient with Alzheimer’s disease,
ranging from the newly diagnosed to those with severe disease.
Donepezil is considered to be cost-effective in moderate Alzheimer’s disease (see below) and there are emerging
views that cost effectiveness may also extend to patients with mild disease (MMSE 21 – 26) mainly due to assumed
reduced costs related to institutionalisation and care.6
It is recommended, due to the complexity of Alzheimer’s disease and dementia treatment in general, that only clinicians
with experience in treating dementia should initiate therapy. In practice this may be difficult but it is advisable to
discuss treatment with a specialist and to become familiar with local protocols and practices. GPs may work in conjunction
with the care team to assess the response to therapy, as the GP is more likely to be familiar with the patient over a
longer time period.
Cost-effectiveness of donepezil in Alzheimer’s disease
Estimates of the cost-effectiveness of donepezil need to make several assumptions around the effects of treatment on
progression to full-time care. The extent that acetylcholinesterase inhibitors delay rest home placement is uncertain,
as the evidence is incomplete and ambiguous.
The AD2000 study, published in 2004, concluded that donepezil provided very minimal clinical benefits and was not cost-effective
in people with mild or moderate disease.7 However, due to low recruitment and methodological issues, many
subsequent reviews or analyses have not incorporated the results of the AD2000 study.
In the National Institute for Clinical Excellence (NICE) guidelines from the United Kingdom it was concluded that donepezil
and other acetylcholinesterase inhibitors are cost-effective, but only in people with moderate Alzheimer’s disease,
and this is the basis of their recommendation for the use of these medicines.2 The main benefits are associated
with assumed cost savings due to delayed full-time institutional dementia care and support.
There is also debate about the cost-effectiveness of donepezil in people with mild Alzheimer’s disease, and whether
there are benefits in starting acetylcholinesterase inhibitors, both on clinical and economic grounds. While the AD2000
trial did not report any benefits in people with mild disease, other more recent cost-effectiveness models for donepezil
in mild to moderate Alzheimer’s disease, support their use in the early stages of the disease.6
The lack of clarity regarding cost-effectiveness reinforces the need to regularly review and assess the response to
donepezil and to stop treatment if it appears ineffective or is not tolerated.
The use of acetylcholinesterase inhibitors in Alzheimer’s disease
Alzheimer’s disease is associated with a decrease in activity of the cholinergic system in the brain. Pharmacological
treatments for Alzheimer’s disease are based on inhibition of acetylcholinesterase, which increases the concentration
of acetylcholine in the brain, resulting in increased cognitive function in some people. This class of drugs have also
been shown to have some effect on other forms of dementia, including vascular dementia.8
There are currently three acetylcholinesterase inhibitors available and registered in New Zealand for the treatment
of Alzheimer’s disease – donepezil (Donepezil-Rex, Aricept, Donezil), galantamine (Reminyl) and rivastigmine
(Exelon). Donepezil-Rex is the only acetylcholinesterase inhibitor that will be funded on the Pharmaceutical Schedule
at this time.
Are acetylcholinesterase inhibitors effective?
Acetylcholinesterase inhibitors improve symptoms related to cognition, behaviour and function for some people with Alzheimer’s
disease.5 However, there is no evidence to show that they slow the underlying progression of the disease.1,2 Minor
improvements in daily activity scores and cognition test results have been observed such as an improvement of one to two
points on the 30 point MMSE test. For some people with Alzheimer’s disease this may mean that they have improved
memory and ability to perform daily tasks, improved quality of life and reduced need for care.
The results of acetylcholinesterase inhibitor therapy are variable, but on average, patients may expect about six months
of preserved cognitive function. Clinically relevant improvement has been measured (using cognitive tests) in approximately
39% of patients taking donepezil versus 22% taking a placebo.2 Increasing the dose of the acetylcholinesterase
inhibitor may result in a greater improvement for some patients, however adverse effects may become intolerable.2,5
Comparing donepezil to other non-funded acetylcholinesterase inhibitors
All three acetylcholinesterase inhibitors available in New Zealand are similarly effective in treating the symptoms
of Alzheimer’s disease and are associated with similar adverse effects. Lack of response to one drug does not necessarily
mean that benefit will not be derived from another.
Like donepezil, galantamine is a selective inhibitor of acetylcholinesterase, however it also enhances the action
of acetylcholine on nicotinic receptors. Nicotinic cholinergic receptors are thought to be important in regulating cognitive
functions such as attention. Galantamine has a longer half-life than donepezil, which could mean that severe adverse
effects persist for longer.2 However, there have been no significant clinical differences demonstrated between
the effect and tolerability of galantamine and donepezil.
Rivastigmine is less selective than donepezil and targets both acetylcholinesterase and butyl-cholinesterase
inhibitors.5 However this increased inhibition does not appear to result in a clinically different effect
than donepezil. Clinical trials used to study rivastigmine have only lasted 24 weeks in duration, therefore it is unproven
whether treatment gains would last longer than six months. Rivastigmine is available as a transdermal patch preparation,
which may be preferable for people who have experienced intolerable adverse gastrointestinal effects with an oral acetylcholinesterase
Memantine is a non-competitive N-methyl D-aspartate (NMDA) receptor antagonist, which is also used for the symptomatic
treatment of Alzheimer’s disease.10 It is thought that malfunction of glutaminergic neurotransmission
at NMDA receptors may contribute to symptom expression and progression of Alzheimer’s disease. Memantine partially
blocks NMDA receptors, inhibiting over-stimulation by the excitatory neurotransmitter glutamate.10 This action
can result in a small symptomatic improvement in cognition, mood and the ability to perform daily tasks, similar to the
functional gain observed in some people taking acetylcholinesterase inhibitors.
The adverse effects of memantine are usually mild and may include influenza-like symptoms, headaches, muscular pain
In general, it is considered that the limited evidence of benefit for memantine is outweighed by the economic costs
involved with the treatment.2,11 Memantine is not currently funded in New Zealand.
Cognitive testing in Alzheimer’s disease and its role in defining progression
Cognitive tests are used to monitor both the progression of Alzheimer’s disease and the treatment effect of pharmacological
agents. The two most commonly used tests in New Zealand are the Mini Mental State Examination (MMSE) and Addenbrooke’s
Cognitive Examination-Revised (ACE-R).
The MMSE is a brief test (approximately ten minutes) that can be used for screening for cognitive impairment and for
estimating severity and progression of Alzheimer’s disease and other forms of dementia. The maximum score on the
MMSE test is 30. Age and education levels may influence scores. Scores above 20 can suggest mild cognitive impairment,
scores between 11 and 20 suggest moderate cognitive impairment and scores of ten or below suggest severe cognitive impairment.
These scores are suggested in the context that a patient has already been clinically diagnosed with Alzheimer’s
disease and a level of cognitive impairment is to be ascertained.
The ACE-R is a simple and effective test that can be administered by any clinician.9 It has been suggested
that it can detect dementia earlier than MMSE though neither test should be used as a means of diagnosing Alzheimer’s
disease. Both tests are useful in assessing patients and helping family and caregivers to understand disease progression.
An online copy of ACE-R can be found at several websites including: www.stvincents.ie/dynamic/File/Addenbrookes_A_SVUH_MedEl_tool.pdf
The Alzheimer’s disease Assessment Scale-cognitive subscale (ADAS-cog) is used for measuring cognitive impairment
and is frequently used as the outcome measure in clinical studies.
Initiating donepezil and assessing treatment response
Clear treatment goals should be set before commencing an acetylcholinesterase inhibitor. As donepezil is the only acetylcholinesterase
inhibitor that is to be funded, it is recommended to trial this medicine first. Other acetylcholinesterase inhibitors
may be trialled if there is no response to donepezil, however this will depend on whether the cost of treatment is able
to be met.
Individual response to donepezil can not be predicted. The duration of treatment should be for as long as the patient
is seen to benefit. The benefits of continuing donepezil should be assessed through the use of periodic evaluations of
the patient’s overall and cognitive function.
- Before initiating donepezil in a person with Alzheimer’s disease it is strongly recommended that a practitioner
experienced in the treatment of dementia is consulted.
- Donepezil should not be considered unless a clear diagnosis of Alzheimer’s disease has been made. There is no
evidence that donepezil is beneficial in people with mild cognitive impairment or that it delays the progression to Alzheimer’s
- Clearly defined treatment aims should be set e.g. decreased carer burden and stress, increased time until long-term
care is needed, stabilisation of memory or cognition, decline in specific behaviours.
- Once the decision has been made to prescribe donepezil, it is recommended that treatment is commenced at 5 mg/day
(once daily dosing, usually taken at night). This dose should be maintained for at least one month before clinical response
is assessed. Monitor for adverse effects.
- If tolerated the dose may be increased to 10 mg/day. Treatment response should be reassessed at three months and again
at six months.
- Reduce the dose to 5 mg/day if adverse effects become intolerable or improved clinical benefit is not apparent.
- If no benefit is observed at either dose, donepezil should be discontinued.
Best Practice Tip: Some DHB areas have specialised “memory
clinics” where patients with Alzheimer’s disease can be diagnosed and treated and families can be supported
in understanding the changes and challenges likely to take place after diagnosis. Contact your local DHB for details of
Pharmacological treatments should be used as part of a wider management plan for Alzheimer’s disease
Management of Alzheimer’s disease involves treatment of cognitive, behavioural and psychological issues. Acetylcholinesterase
inhibitors such as donepezil can have a beneficial effect on cognitive symptoms, patient function, behaviour and reduce
the burden on caregivers, but they are not a cure. The wider management of patients with Alzheimer’s disease includes
educating patients, their caregivers and family on the nature of the disease and how to deal with the inevitable decline
in the patient’s cognitive function and their ability to care for themselves. The role of clinicians in this education
process and in the overall management of the disease is important.
For more information about identifying early signs of cognitive decline in older
people, see BPJ 23 (Sept 2009); “Having a Senior Moment”.
Assessing response to treatment
It is important to explain to both the patient and their family that pharmacological therapy for Alzheimer’s disease
is largely symptomatic. Acetylcholinesterase inhibitors can improve quality of life and cognitive function in many patients,
but these gains are only temporary. Family and caregivers are often involved in observing for treatment response and adverse
Potential adverse effects should be discussed prior to treatment as they can affect the way treatment goals are set.
For example, if the goal for therapy is to increase the quality of life then the extent of the adverse effects can play
a large role in deciding if, and when, to cease therapy.
- Assess cognitive function and activities of daily living prior to starting treatment using cognitive tests such as
MMSE or ACE-R and self-reported and family observation of behaviours
- Assess initial treatment response after one month
- After three months at the highest tolerated dose, assess cognitive response to therapy
- If cognitive test scores indicate improvement (or no deterioration) and there is evidence of functional or behavioural
improvement, continue treatment
- Treatment for longer than six months should be based on clear response and adequate ability for monitoring of the
Adverse effects, precautions and drug interactions
Mild cholinergic adverse effects such as vomiting and nausea affect approximately 20% of people taking acetylcholinesterase
inhibitors. Other adverse effects associated with donepezil may include fatigue, dizziness, headache, syncope, bradycardia,
agitation, confusion, dyspepsia, increased sweating and tremor.
Adverse effects are dose dependent, usually of short duration, and resolve spontaneously or after dose reduction. Adverse
effects may be minimised by initiating treatment at a low dose, i.e. 5 mg donepezil, and increasing the dose gradually,
i.e. after one month.
N.B. Each acetylcholinesterase inhibitor has a slightly different adverse effect profile. Refer to the manufacturer’s
Precautions to the use of donepezil include: asthma, COPD, epilepsy or seizure disorder, urinary retention
and a history of peptic ulcers.
As donepezil and other acetylcholinesterase inhibitors may cause bradycardia, particular caution is required in prescribing
to people with significant bradycardia, sick sinus syndrome or other superventricular cardiac conduction disturbances,
such as sinoatrial or atrioventricular block.
All acetylcholinesterase inhibitors have the potential to increase the risk of bradycardia with beta blockers, digoxin,
amiodarone and calcium channel blockers. The actions of other anticholinergic drugs, e.g. oxybutinin and benztropine,
may be antagonised.
Donepezil is metabolised in the liver but there appear to be few clinically significant drug interactions involving
the cytochrome p450 system. There is a possibility that enzyme inhibitors, e.g. fluoxetine, paroxetine and erythromycin,
may increase drug concentrations of donepezil, and enzyme inducers, e.g. phenytoin and carbamazepine, may reduce drug
concentrations. However, such interactions do not appear to be clinically significant.
Treatment with donepezil or any other acetylcholinesterase inhibitor should be discontinued if:
- Significant adverse effects occur
- There is poor adherence to the treatment regimen or monitoring requirements
- Treatment goals are not achieved or major deterioration in the patient’s condition occurs
After donepezil is discontinued beneficial effects usually abate gradually. There is little evidence to suggest a rebound
effect after abrupt cessation of donepezil, however in practice this is sometimes observed. Sudden loss of cognitive function
is possible and patients should be supported and monitored prior to, and during, the cessation period.
Thank you to Dr Gary Cheung and Dr Richard Worrall, Specialist Psychogeriatricians,
Greenlane Clinical Centre, Auckland DHB for expert guidance in developing this article.